ClinicalTrials.gg
Enrolling by invitationNCT06679946Updated Oct 21, 2026

A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

A Phase 3 interventional study of Vutrisiran in Transthyretin Amyloidosis (ATTR) With Cardiomyopathy, sponsored by Alnylam Pharmaceuticals. Enrolling by invitation at 87 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Alnylam Pharmaceuticals · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
700
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 12 studies in Amyloidosis, Hereditary, Transthyretin-Related by Alnylam Pharmaceuticals — 2 open to participants now, 4 under way, 2 of them phase 3. Amyloidosis, Hereditary, Transthyretin-Related · Alnylam Pharmaceuticals.

Started
2024
with 1 other
Phase 3
7 of 12
1 open now
Registered
12th of 12
by date

Among the 12 studies in Amyloidosis, Hereditary, Transthyretin-Related by Alnylam Pharmaceuticals, this one is one of 2 that started in 2024, is one of 7 in phase 3, and was the 12th registered.

Amyloidosis, Hereditary, Transthyretin-Related

82 studies on the registry are indexed under Amyloidosis, Hereditary, Transthyretin-Related; 28 are open to participants now.

Browse Amyloidosis, Hereditary, Transthyretin-Related studies →

Open to participants now

2 of the 12 studies in Amyloidosis, Hereditary, Transthyretin-Related by Alnylam Pharmaceuticals are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 22 Amyloidosis, Hereditary, Transthyretin-Related studies recruiting now, 15 (68%) set no upper age limit and 1 (5%) stops at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Amyloidosis, Hereditary, Transthyretin-Related by Alnylam Pharmaceuticals, or all of them as a file.
02

Study summary

The purpose of this study is to obtain safety, efficacy, and pharmacodynamic data on the use of vutrisiran in patients with ATTR amyloidosis with cardiomyopathy who continued on extended use of vutrisiran, or switched from patisiran.

03

Conditions studied

  • Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

Keywords

  • ATTR
  • Cardiomyopathy
  • Amylodosis
  • TTR
  • Transthyretin
  • TTR-mediated amyloidosis
  • Amyloidosis, Hereditary, Transthyretin-Related
  • RNAi therapeutic
  • Transthyretin amyloid cardiomyopathy
  • TTR cardiomyopathy
  • ATTR-CM
  • Wild-type TTR
  • V122I
  • TTR amyloidosis
  • Amyloidosis, Wild Type
  • hATTR amyloidosis with cardiomyopathy
  • ATTR amyloidosis with cardiomyopathy
  • wtATTR amyloidosis with cardiomyopathy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who are participating in the patisiran parent studies ALN-TTR02-011 or ALN-TTR02-014 or who have completed the 24-month OLE Period in the vutrisiran parent study ALN-TTRSC02-003

Exclusion criteria

Exclusion Criteria:

  • Has permanently discontinued study drug administration while participating in the parent studies, ALN-TTR02-011, ALN-TTR02-014, or ALN-TTRSC02-003
  • Future or current participation in another device or drug study, scheduled to occur during this study
  • Has other medical conditions or comorbidities which, in the opinion of the Investigator, would interfere with study compliance or data interpretation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
700 participants (estimated)

Study arms

  • Experimental
    Vutrisiran 25 mg

    Participants will receive vutrisiran 25 mg administered subcutaneously (SC) once every 3 months (q3M).

    Drug: Vutrisiran

Interventions

  • Vutrisiran administered SC q3M

    Also known as: ALN-TTRSC02, AMVUTTRA®

06

What researchers measure

Primary outcomes

  1. Frequency of Adverse Events (AEs)

    An AE is any untoward medical occurrence in a patient or clinical investigational subject administered a medicinal product and which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to 36 Months

Secondary outcomes

  1. Change from Baseline in the Kansas City Cardiomyopathy Questionnaire Overall Summary (KCCQ-OS)

    The KCCQ is a 23-item self-administered questionnaire quantifying 6 domains (symptoms, physical function, quality of life, social limitation, self-efficacy, and symptom stability) and 2 summary scores (clinical and overall summary \[OS\]). Scores are transformed to a range of 0-100, in which higher scores reflect better health status.

    Time frame: Baseline up to 36 Months

  2. Change from Baseline in New York Heart Association (NYHA) Class

    NYHA classification grades the severity of heart failure symptoms into the following stages: I (no symptoms; ordinary physical activity such as walking and climbing stairs does not cause fatigue or dyspnea), II (symptoms with ordinary physical activity; walking or climbing stairs rapidly, walking uphill, walking or stair climbing after meals, in cold weather, in wind or when under emotional stress causes undue fatigue or dyspnea), III (symptoms with less than ordinary physical activity; walking 1 to 2 blocks on the level and climbing more than 1 flight of stairs in normal conditions causes undue fatigue or dyspnea), IV (symptoms at rest; inability to carry on any physical activity without fatigue or dyspnea).

    Time frame: Baseline up to 36 Months

  3. Change From Baseline in the Cardiac Biomarker: N-terminal Prohormone of B-type Natriuretic Peptide (NT-proBNP)

    NT-proBNP will be assessed through measurement of serum levels.

    Time frame: Baseline up to 36 Months

  4. Change From Baseline in the Cardiac Biomarker: Troponin I

    Troponin I will be assessed through measurement of serum levels.

    Time frame: Baseline up to 36 Months

  5. All-Cause Mortality and Recurrent Cardiovascular (CV) Events (CV Hospitalizations and Urgent Heart Failure [HF] Visits)

    All deaths, hospitalizations and urgent HF visits will be recorded throughout the study as part of SAE and AE monitoring

    Time frame: Up to 36 Months

  6. Change from baseline in serum TTR level

    Time frame: Baseline, Month 6 and Month 12

07

Study locations

87 sites
  • Clinical Trial Site
    Phoenix, Arizona 85054, United States
  • Clinical Trial Site
    Beverly Hills, California 90211, United States
  • Clinical Trial Site
    La Jolla, California 92037, United States
  • Clinical Trial Site
    Stanford, California 94305, United States
  • Clinical Trial Site
    Washington D.C., District of Columbia 20010, United States
  • Clinical Trial Site
    Chicago, Illinois 60637, United States
  • Clinical Trial Site
    Glenview, Illinois 60026, United States
  • Clinical Trial Site
    Indianapolis, Indiana 46202, United States
  • Clinical Trial Site
    Kansas City, Kansas 66160, United States
  • Clinical Trial Site
    Baltimore, Maryland 21287, United States
  • Clinical Trial Site
    Boston, Massachusetts 02115, United States
  • Clinical Trial Site
    Boston, Massachusetts 02118, United States
  • Clinical Trial Site
    Rochester, Minnesota 55905, United States
  • Clinical Trial Site
    St Louis, Missouri 63110, United States
  • Clinical Trial Site
    Omaha, Nebraska 68198, United States
  • Clinical Trial Site
    New York, New York 10029, United States
  • Clinical Trial Site
    New York, New York 10032, United States
  • Clinical Trial Site
    Durham, North Carolina 27710, United States
  • Clinical Trial Site
    Cleveland, Ohio 44195, United States
  • Clinical Trial Site
    Columbus, Ohio 43214, United States
  • Clinical Trial Site
    Philadelphia, Pennsylvania 19104, United States
  • Clinical Trial Site
    Nashville, Tennessee 37232, United States
  • Clinical Trial Site
    Dallas, Texas 75246, United States
  • Clinical Trial Site
    Salt Lake City, Utah 84132, United States
  • Clinical Trial Site
    Buenos Aires, C1093AAS, Argentina
  • Clinical Trial Site
    Buenos Aires, C1199ABB, Argentina
  • Clinical Trial Site
    Buenos Aires, C1428, Argentina
  • Clinical Trial Site
    Córdoba, X5000KEH, Argentina
  • Clinical Trial Site
    Rosario, S2000DEJ, Argentina
  • Clinical Trial Site
    Rosario, S2000DSR, Argentina
  • Clinical Trial Site
    Rosario, S2000PBJ, Argentina
  • Clinical Trial Site
    Vienna, 1090, Austria
  • Clinical Trial Site
    Vienna, 1210, Austria
  • Clinical Trial Site
    Aalst, 9300, Belgium
  • Clinical Trial Site
    Anderlecht, 1070, Belgium
  • Clinical Trial Site
    Dendermonde, 9200, Belgium
  • Clinical Trial Site
    Ghent, 9000, Belgium
  • Clinical Trial Site
    Hasselt, 3500, Belgium
  • Clinical Trial Site
    Leuven, 3000, Belgium
  • Clinical Trial Site
    Liège, 4000, Belgium
  • Clinical Trial Site
    Roeselare, 8800, Belgium
  • Clinical Trial Site
    Ribeirão Preto, 14026-900, Brazil
  • Clinical Trial Site
    Ribeirão Preto, 14051-140, Brazil
  • Clinical Trial Site
    Rio de Janeiro, 22280-020, Brazil
  • Clinical Trial Site
    São Paulo, 04012-180, Brazil
  • Clinical Trial Site
    São Paulo, 05403-000, Brazil
  • Clinical Trial Site
    Prague, 120 00, Czechia
  • Clinical Trial Site
    Prague, 128 21, Czechia
  • Clinical Trial Site
    Prague, 140 21, Czechia
  • Clinical Trial Site
    Aarhus N, 8200, Denmark
  • Clinical Trial Site
    København Ø, 2100, Denmark
  • Clinical Trial Site
    Odense C, 5000, Denmark
  • Clinical Trial Site
    Créteil, 94000, France
  • Clinical Trial Site
    Marseille, 13005, France
  • Clinical Trial Site
    Paris, 75018, France
  • Clinical Trial Site
    Rennes, 35000, France
  • Clinical Trial Site
    Toulouse, 31059, France
  • Clinical Trial Site
    Bologna, 40138, Italy
  • Clinical Trial Site
    Florence, 50134, Italy
  • Clinical Trial Site
    Pavia, 27100, Italy
  • Clinical Trial Site
    Groningen, 9713 GZ, Netherlands
  • Clinical Trial Site
    Maastricht, 6229 HX, Netherlands
  • Clinical Trial Site
    Utrecht, 3584 CX, Netherlands
  • Clinical Trial Site
    Oslo, 372, Norway
  • Clinical Trial Site
    Creixomil, 4835-044, Portugal
  • Clinical Trial Site
    Lisbon, 1649-035, Portugal
  • Clinical Trial Site
    Porto, 4099-001, Portugal
  • Clinical Trial Site
    Viseu, 3504-509, Portugal
  • Clinical Trial Site
    Seoul, 03080, South Korea
  • Clinical Trial Site
    Seoul, 03722, South Korea
  • Clinical Trial Site
    Seoul, 06351, South Korea
  • Clinical Trial Site
    Barcelona, 08035, Spain
  • Clinical Trial Site
    Bilbao, 48013, Spain
  • Clinical Trial Site
    L'Hospitalet de Llobregat, 8907, Spain
  • Clinical Trial Site
    Madrid, 28222, Spain
  • Clinical Trial Site
    Málaga, 29010, Spain
  • Clinical Trial Site
    Gothenburg, 413 45, Sweden
  • Clinical Trial Site
    Solna, 171 76, Sweden
  • Clinical Trial Site
    Umeå, 907 37, Sweden
  • Clinical Trial Site
    Taipei, 112, Taiwan
  • Clinical Trial Site
    Bellshill, ML4 3NJ, United Kingdom
  • Clinical Trial Site
    Birmingham, B15 2SQ, United Kingdom
  • Clinical Trial Site
    Cardiff, CF15 9SS, United Kingdom
  • Clinical Trial Site
    Hexham, NE46 1QJ, United Kingdom
  • Clinical Trial Site
    London, NW3 2QG, United Kingdom
  • Clinical Trial Site
    London, SE1 1YR, United Kingdom
  • Clinical Trial Site
    Manchester, M15 6SE, United Kingdom
08

References and documents

Publications

  • Fontana M, Berk JL, Gillmore JD, Witteles RM, Grogan M, Drachman B, Damy T, Garcia-Pavia P, Taubel J, Solomon SD, Sheikh FH, Tahara N, Gonzalez-Costello J, Tsujita K, Morbach C, Pozsonyi Z, Petrie MC, Delgado D, Van der Meer P, Jabbour A, Bondue A, Kim D, Azevedo O, Hvitfeldt Poulsen S, Yilmaz A, Jankowska EA, Algalarrondo V, Slugg A, Garg PP, Boyle KL, Yureneva E, Silliman N, Yang L, Chen J, Eraly SA, Vest J, Maurer MS; HELIOS-B Trial Investigators. Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy. N Engl J Med. 2025 Jan 2;392(1):33-44. doi: 10.1056/NEJMoa2409134. Epub 2024 Aug 30. PubMed 39213194 ↗

Individual participant data

Plan to share: Yes — Access to Anonymized individual participant data that support these results is made available 12 months after study completion and not less than 12 months after the product and indication have been approved in the US and/or the EU. Access to data may be declined where there is likelihood a patient could be identified or other feasibility issue, where there is a potential conflict of interest, a planned business activities or an actual or potential competitive risk. Data will be provided contingent upon the approval of a research proposal and the execution of a data sharing agreement. Timeframes for data access may vary and can take up to 6 months or more. Requests for access to data can be submitted via the website www.vivli.org. Questions can also be directed to datasharing@alnylam.com.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2024 (actual). Primary completion is estimated for Mar 2028, 39 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2024
First posted
Nov 8, 2024
StartActual
Dec 3, 2024
Primary completionEst.
Mar 31, 2028
CompletionEst.
Mar 31, 2028
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and site details
1 update, last Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Minor edits only
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06679946
Responsible party
Sponsor
First posted
Nov 8, 2024
Start date
Dec 3, 2024
Primary completion
Mar 31, 2028 (estimated)
Completion
Mar 31, 2028 (estimated)
Last update
Oct 21, 2026

Study contacts

Medical Director
study director · Alnylam Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vutrisiran

Start the discussion